Israel Englander Bio Atla, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 116,661 shares of BCAB stock, worth $43,164. This represents 0.0% of its overall portfolio holdings.

Number of Shares

116,661

Previous 1,095,606 89.35%

Holding current value

$43,164

Previous $646,000 93.81%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.28 - $0.68 $274,104 - $665,682	-978,945 Reduced 89.35%	116,661 $40,000
Q4 2024 Feb 14, 2025	SELL	$0.59 - $2.37 $922,749 - $3.71 Million	-1,563,983 Reduced 58.81%	1,095,606 $646,000
Q3 2024 Nov 14, 2024	BUY	$1.17 - $2.05 $1.18 Million - $2.07 Million	1,010,327 Added 61.26%	2,659,589 $4.68 Million
Q2 2024 Aug 14, 2024	BUY	$1.37 - $3.92 $1.06 Million - $3.04 Million	775,608 Added 88.78%	1,649,262 $2.26 Million
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $1.23 Million - $2.27 Million	654,854 Added 299.29%	873,654 $3.01 Million
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $84,175 - $210,770	-66,280 Reduced 23.25%	218,800 $538,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $286,942 - $392,390	101,393 Added 55.2%	285,080 $855,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $187,730 - $673,381	81,622 Added 79.97%	183,687 $492,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $445,218 - $779,309	70,782 Added 226.26%	102,065 $842,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $429,316 - $1.73 Million	-146,026 Reduced 82.36%	31,283 $241,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

13.9M

Call Options Held

20.3K

Put Options Held

1.2K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $13.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account